Fate Therapeutics, Inc. - FATE STOCK NEWS

Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company, which focuses on developing iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, will present on Thursday, September 19, 2024, at 12:45 PM ET in New York.

Investors and interested parties can access a live webcast of the presentation through the 'Events & Presentations' section of Fate Therapeutics' website. The archived version will be available shortly after the event concludes. This conference appearance provides an opportunity for Fate Therapeutics to showcase its innovative pipeline and progress in the field of cellular immunotherapies to a global audience of healthcare professionals and investors.

Fate Therapeutics (NASDAQ: FATE) reported Q2 2024 financial results and business updates. Key highlights include:

1. Ongoing enrollment in FT819 Phase 1 autoimmunity study for SLE, now including single-agent cyclophosphamide as an alternative conditioning regimen.

2. First patient treated with FT522 CAR NK cell product in conditioning-free arm of Phase 1 B-cell lymphoma study.

3. FT522 multi-indication IND for autoimmune diseases to be submitted in Q3 2024.

4. Enrollment ongoing for FT825/ONO-8250 CAR T-cell product in Phase 1 solid tumor study.

5. $352 million in cash and investments, with projected runway through 2026.

6. Q2 2024 revenue of $6.8 million, including a $5 million milestone from Ono Pharmaceutical.

7. GAAP operating expenses of $51.9 million for Q2 2024.

Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on developing iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, has announced new employee inducement awards. On August 1, 2024, the company granted restricted stock units (RSUs) representing 34,200 shares of common stock to four newly-hired non-executive employees. These grants were approved by the Compensation Committee and issued under the company's Amended and Restated Inducement Equity Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting annually, contingent on continuous employment.

Fate Therapeutics (NASDAQ: FATE) has appointed Dr. Neely Mozaffarian to its Board of Directors. Dr. Mozaffarian brings over 20 years of experience in immunology and autoimmunity research and drug development. This appointment comes as Fate Therapeutics expands its clinical investigation of iPSC-derived cell products for autoimmune diseases.

The company recently treated its first systemic lupus erythematosus patient with FT819, an off-the-shelf, iPSC-derived CD8αβ+ T-cell product candidate. The patient, a 27-year-old woman with refractory disease, received a single dose of 360 million cells and was discharged after three days without notable adverse events.

Dr. Mozaffarian's expertise is expected to benefit Fate Therapeutics as it advances its pipeline of cell therapies for autoimmune conditions. Her background includes leadership roles at Atomwise, GentiBio, Janssen Pharmaceuticals, and other major pharmaceutical companies.

Fate Therapeutics, a clinical-stage biopharmaceutical company focused on induced pluripotent stem cell (iPSC)-derived cellular immunotherapies, announced employee inducement awards under Nasdaq Listing Rule 5635(c)(4). On July 1, 2024, the company granted restricted stock units (RSUs) totaling 28,200 shares of common stock to three newly-hired non-executive employees. These grants were approved by the Compensation Committee and will vest over four years, with 25% vesting annually, contingent on the employees' continuous employment.

Fate Therapeutics, a clinical-stage biopharmaceutical company focusing on iPSC-derived cellular immunotherapies for cancer and autoimmune disorders, announced new employee inducement awards under Nasdaq Listing Rule 5635(c)(4). On June 1, 2024, the company granted a non-qualified stock option to one new employee to purchase a total of 65,000 shares at an exercise price of $3.68 per share, the closing price on May 31, 2024. Additionally, Fate Therapeutics granted restricted stock units (RSUs) representing 14,500 shares to three new non-executive employees. These grants were approved by the Compensation Committee and are part of the company's Amended and Restated Inducement Equity Plan. Both the stock options and RSUs will vest over four years, contingent on continuous employment.

Fate Therapeutics, a clinical-stage biopharmaceutical company focusing on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, announced their participation in the 2024 Jefferies Global Healthcare Conference. The presentation is scheduled for June 5, 2024, at 3:00 PM ET in New York. The event will be webcasted live and accessible on the Company’s website, with an archived version available post-event.

Fate Therapeutics reported its first quarter 2024 financial results and business updates, highlighting progress in clinical areas, including treating the first lupus patient with FT819 CAR T-cell therapy, initiating enrollment for FT522 CAR NK cell therapy, and treating the first patient with FT825 CAR T-cell therapy. The company has $391 million in cash, cash equivalents, and investments. The financial results include $1.9 million in revenue, $53.0 million in operating expenses, and total outstanding shares of 113.8 million.

Fate Therapeutics announced the treatment of the first lupus patient in the Phase 1 autoimmunity study of FT819 CAR T-cell program. The patient showed rapid and potent depletion of CD19+ B cells. The company also presented translational data from the Phase 1 study of FT819 in B-cell malignancies and initial clinical observations from the FT522 CAR NK cell program in B-cell lymphoma. These programs highlight key therapeutic mechanisms for autoimmune diseases.